Cytomegalovirus Drug Resistance Typing EQA/PT Scheme

To assess the laboratories’ ability to detect CMV drug resistance mutations in kinase UL97, polymerase UL54 gene and the UL56 that forms part of the terminase, using sequencing techniques.

Total Number of Challenges: 1
Number of Panel Members: 4
Distribution / Testing Period: Q2
Sample NA Target Source Cultured and/or Clinical material
Matrix Panel Format Plasma and/or Physiological Buffer
Panel Member Target Range Various mutations – kinase (UL97), polymerase (UL54) and terminase (UL56) genes
Panel Member Sample Volume 1.0 ml
Panel Sample Pre-treatment Requirement Ready for analysis. Treat as clinical samples and analyse accordingly.
Panel Analysis Type Sequence Analysis
Panel Testing Evaluated by various molecular methodologies
Storage / Shipment Conditions <-20°C / Frozen on Dry-ice
Accreditation / Regulatory Status Accredited to ISO 17043
SKU: QAV144169_1 Categories: , , , , , Tags: ,

$1,426.53